Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points - European Medical Journal
×

Browse

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points

| Download as | PDF
Chairpeople:
Fred Saad1
Speakers:
Gero Kramer,2 Bertrand Tombal,3 Jürgen Gschwend4
Disclosure:

Professor Saad has received advisory board and/or research funding from Abbott, Amgen, Astellas, Bayer, Janssen, Millennium, Novartis, and Sanofi. Professor Kramer has received scientific advisory board/honoraria from Sanofi, Bayer, Janssen, Takeda, Astellas, Ipsen, and Pfizer. Professor Tombal has acted as an investigator for Astellas, Bayer, Ferring, Janssen, Medivation, Sanofi, and Takeda, and as a paid consultant or speaker for Amgen, Astellas, Bayer, Ferring, Medivation, Sanofi, and Takeda. Professor Gschwend has received honoraria from Amgen, Astellas, Bayer, Janssen, Novartis, and PierreFabre, and advisory board fees from Amgen, Astellas, Bayer, BMS, Janssen, Novartis, Pfizer, Pierre-Fabre, Roche, and Teva.

Acknowledgements:

Writing assistance was provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Bayer. The views and opinions expressed are those of the authors and not necessarily of Bayer.

Citation
EMJ Urol. ;3[2]:57-62.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC). Results from the recent Phase III ALpharadin in SYMptomatic Prostate Cancer (ALSYMPCA) study were also presented. Profs Kramer, Tombal, and Gschwend then each presented case studies on patients they had treated with radium-223. Each speaker also provided their own personal view and recommendations for use of radium-223 based on their experience with these patients. Prof Gschwend concluded the symposium with important considerations for the urologist in using radium-223 in mCRPC.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.